Cargando…

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment

Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal e...

Descripción completa

Detalles Bibliográficos
Autores principales: Eltahla, Auda A., Leung, Preston, Pirozyan, Mehdi R., Rodrigo, Chaturaka, Grebely, Jason, Applegate, Tanya, Maher, Lisa, Luciani, Fabio, Lloyd, Andrew R., Bull, Rowena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282498/
https://www.ncbi.nlm.nih.gov/pubmed/28139734
http://dx.doi.org/10.1038/srep41719
_version_ 1782503333443928064
author Eltahla, Auda A.
Leung, Preston
Pirozyan, Mehdi R.
Rodrigo, Chaturaka
Grebely, Jason
Applegate, Tanya
Maher, Lisa
Luciani, Fabio
Lloyd, Andrew R.
Bull, Rowena A.
author_facet Eltahla, Auda A.
Leung, Preston
Pirozyan, Mehdi R.
Rodrigo, Chaturaka
Grebely, Jason
Applegate, Tanya
Maher, Lisa
Luciani, Fabio
Lloyd, Andrew R.
Bull, Rowena A.
author_sort Eltahla, Auda A.
collection PubMed
description Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types.
format Online
Article
Text
id pubmed-5282498
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52824982017-02-03 Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment Eltahla, Auda A. Leung, Preston Pirozyan, Mehdi R. Rodrigo, Chaturaka Grebely, Jason Applegate, Tanya Maher, Lisa Luciani, Fabio Lloyd, Andrew R. Bull, Rowena A. Sci Rep Article Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types. Nature Publishing Group 2017-01-31 /pmc/articles/PMC5282498/ /pubmed/28139734 http://dx.doi.org/10.1038/srep41719 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Eltahla, Auda A.
Leung, Preston
Pirozyan, Mehdi R.
Rodrigo, Chaturaka
Grebely, Jason
Applegate, Tanya
Maher, Lisa
Luciani, Fabio
Lloyd, Andrew R.
Bull, Rowena A.
Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title_full Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title_fullStr Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title_full_unstemmed Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title_short Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
title_sort dynamic evolution of hepatitis c virus resistance-associated substitutions in the absence of antiviral treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282498/
https://www.ncbi.nlm.nih.gov/pubmed/28139734
http://dx.doi.org/10.1038/srep41719
work_keys_str_mv AT eltahlaaudaa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT leungpreston dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT pirozyanmehdir dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT rodrigochaturaka dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT grebelyjason dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT applegatetanya dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT maherlisa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT lucianifabio dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT lloydandrewr dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment
AT bullrowenaa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment